A Double-blind, Randomised, Placebo-controlled, Multi-center Study to Evaluate Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Estetrol (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Pantarhei Oncology
- 19 Nov 2019 Planned End Date changed from 30 May 2019 to 30 Dec 2020.
- 19 Nov 2019 Planned primary completion date changed from 30 May 2019 to 30 Jul 2020.
- 31 Aug 2018 Biomarkers information updated